Thanks mate. What i asked was is it possible not if you or...

First 71 Last

Share
Profile

Follow
ayy.ess

90 Posts.

4

11/08/16

10:41

Post #: 18493061
Share

Originally posted by Waterblunt ↑

LMAO.

This is not necessarily directed at you mate.....but are we starting a whole new wave of Sumitomo paranoia again?

They were a legitimate obstacle when the litigation was underway, but it is over and they are not an issue for us anymore.

Ask yourself .....

1. Do the Solomon Islands Government need mining to commence to meet both internal and external financial commitments? Answer.......YES!

2. How long have Sumitomo been in the Solomon Islands and how much have they mined there? Answer.......A VERY long time and ZERO!

3. Have Axiom genuinely attempted to progress to mining at each and every available opportunity? Answer.......YES!

4. Again, is mining really what the Solomon Islands Government want and NEED? Answer.......YES!

So does anyone really think they will chose Sumitomo (so they can land bank more tenements), over us and if so what do you base this assumption on as I simply just can't see it happening. There is more chance of it going to a third party and I can't see that happening either.

GLTAH and Jazz.

Expand

Thanks mate. What i asked was is it possible not if you or anyone else thinks it will happen. If you think the unexpected cant happen then you need to refresh your memory. Currently not holding Axiom and unsure whether i should buy back in or not. Thanks for your personal opinion.

AVQ Price at posting: 25.5¢ Sentiment: Hold Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

FFM

Firefly positioned for copper growth in Canada ahead of resource update

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals